Aim: COVID-19 infection caused by the SARS-CoV-2 virus emerged in Wuhan, China, in December 2019 and rapidly became a global pandemic. There is still a need for markers to predict disease severity and prognosis.
The aim of this retrospective study was to evaluate the relationship between the ferritin-procalcitonin ratio (FPR) and disease severity and prognosis in patients followed up with COVID-19 pneumonia.
Materials and methods: The study included patients with COVID-19 pneumonia confirmed by real-time polymerase chain reaction test positivity on nasal and pharyngeal smear samples.
Results: Evaluation was made of 2120 cases, comprising 1155 (54.5%) males and 965 (45.5%) females. FPR was determined to be statistically significantly lower in non-survivors, those admitted to the Intensive Care Unit, and those with diabetes, hypertension, chronic obstructive pulmonary disease, coronary artery disease, cancer, or chronic renal failure (p
Key words: COVID-19, disease severity, ferritin/procalcitonin ratio
|
